✦ LIBER ✦

A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

✍ Scribed by Zarah Glad Zimling, Jens Benn Sørensen…

Book ID: 120776529
Publisher: Springer
Year: 2012
Tongue: English
Weight: 813 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1965-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PP 15 BRCA1 expression is required for e

PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma

✍ S. Busacca; M. Sheaff; S.G. Gray; K.J. O'Byrne; K. Kerr; I. Schmitt-Opitz; A. So 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Mesothelin is a biomarker of tumor aggre

Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM)

✍ Elliot L. Servais; Christos Colovos; Kei Suzuki; Marissa Velez; Luis Rodriguez; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Phase II trial of vinorelbine and oxalip

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma

✍ Fennell, Dean A.; C. Steele, Jeremy P.; Shamash, Jonathan; Sheaff, Michael T.; E 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 163 KB

CN2 VALUE-FOR-MONEY OF PEMETREXED PLUS C

CN2 VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA

✍ P Davey; A Cordony; N Rajan; B Arora; N Pavlakis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Cisplatin in combination with irinotecan

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : A pilot phase II clinical trial and pharmacokinetic profile

✍ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci

In vivo Loss of Expression of Argininosu

In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion

✍ Szlosarek, P. W.; Klabatsa, A.; Pallaska, A.; Sheaff, M.; Smith, P.; Crook, T.; 📂 Article 📅 2006 🏛 American Association for Cancer Research 🌐 English ⚖ 350 KB